In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice.

Porous silicon (pSi) is being extensively studied as an emerging material for use in biomedical applications, including drug delivery, based on the biodegradability and versatile chemical and biophysical properties. We have recently introduced multistage nanoporous silicon microparticles (S1MP) designed as a cargo for nanocarrier drug delivery to enable the loaded therapeutics and diagnostics to sequentially overcome the biological barriers in order to reach their target. In this first report on biocompatibility of intravenously administered pSi structures, we examined the tolerability of negatively (-32.5±3.1mV) and positively (8.7±2.5mV) charged S1MP in acute single dose (10(7), 10(8), 5×10(8) S1MP/animal) and subchronic multiple dose (10(8) S1MP/animal/week for 4 weeks) administration schedules. Our data demonstrate that S1MP did not change plasma levels of renal (BUN and creatinine) and hepatic (LDH) biomarkers as well as 23 plasma cytokines. LDH plasma levels of 145.2±23.6, 115.4±29.1 vs. 127.0±10.4; and 155.8±38.4, 135.5±52.3 vs. 178.4±74.6 were detected in mice treated with 10(8) negatively charged S1MP, 10(8) positively charged S1MP vs. saline control in single and multiple dose schedules, respectively. The S1MPs did not alter LDH levels in liver and spleen, nor lead to infiltration of leukocytes into the liver, spleen, kidney, lung, brain, heart, and thyroid. Collectively, these data provide evidence of a safe intravenous administration of S1MPs as a drug delivery carrier.

[1]  David M. Brown,et al.  Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. , 2001, Toxicology and applied pharmacology.

[2]  Y. Liu,et al.  Immunostimulatory properties and enhanced TNF- α mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles , 2009, Nanotechnology.

[3]  M. Ferrari,et al.  Microfabrication of Silicon-Based Nanoporous Particulates for Medical Applications , 2003 .

[4]  K. Leslie,et al.  Biphasic cellular and tissue response of rat lungs after eight-day aerosol exposure to the silicon dioxide cristobalite. , 1989, The American journal of pathology.

[5]  W. Freeman,et al.  Porous silicon in drug delivery devices and materials. , 2008, Advanced drug delivery reviews.

[6]  Mauro Ferrari,et al.  Adhesion of Microfabricated Particles on Vascular Endothelium: A Parametric Analysis , 2004, Annals of Biomedical Engineering.

[7]  G. Jiang,et al.  Preparation of a biochip on porous silicon and application for label-free detection of small molecule-protein interactions. , 2007, Rapid communications in mass spectrometry : RCM.

[8]  Michael J Sailor,et al.  The Compatibility of Hepatocytes with Chemically Modified Porous Silicon with Reference to in Vitro Biosensors , 2022 .

[9]  Mauro Ferrari,et al.  The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. , 2009, Biomaterials.

[10]  A. Cerami.  Inflammatory cytokines. , 1992, Clinical immunology and immunopathology.

[11]  Mauro Ferrari,et al.  Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.

[12]  Leigh T. Canham,et al.  Properties of Porous Silicon , 1998 .

[13]  Mauro Ferrari,et al.  Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. , 2009, Journal of proteome research.

[14]  Marina A Dobrovolskaia,et al.  Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.

[15]  Mauro Ferrari,et al.  Mitotic trafficking of silicon microparticles. , 2009, Nanoscale.

[16]  Sei-Young Lee,et al.  Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows , 2009, Nanotechnology.

[17]  J. Salonen,et al.  Mesoporous silicon in drug delivery applications. , 2008, Journal of pharmaceutical sciences.

[18]  W Kenneth Ward,et al.  A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis. , 2008, Journal of diabetes science and technology.

[19]  Mauro Ferrari,et al.  Tailored porous silicon microparticles: fabrication and properties. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.

[20]  L. Canham.  Bioactive silicon structure fabrication through nanoetching techniques , 1995 .

[21]  R. Aitken,et al.  Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Mauro Ferrari,et al.  Porous Silicon Particles for Imaging and Therapy of Cancer , 2010 .

[23]  Mauro Ferrari,et al.  Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. , 2010, Journal of biomedical materials research. Part A.

[24]  Mauro Ferrari,et al.  Controlled-release microchips , 2006, Expert opinion on drug delivery.

[25]  Mauro Ferrari,et al.  Physicochemically modified silicon as a substrate for protein microarrays. , 2007, Biomaterials.

[26]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[27]  Y. Yoshioka,et al.  Size-dependent cytotoxic effects of amorphous silica nanoparticles on Langerhans cells. , 2010, Die Pharmazie.

[28]  Ron C. Hardman.  A Toxicologic Review of Quantum Dots: Toxicity Depends on Physicochemical and Environmental Factors , 2005, Environmental health perspectives.

[29]  K. Martin,et al.  The chemistry of silica and its potential health benefits. , 2007, The journal of nutrition, health & aging.

[30]  Mauro Ferrari,et al.  Nanomedicine—Challenge and Perspectives , 2009 .

[31]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[32]  Volker Lehmann,et al.  Porous silicon formation: A quantum wire effect , 1991 .

[33]  J. West,et al.  Nano-C60 cytotoxicity is due to lipid peroxidation. , 2005, Biomaterials.

[34]  V. Kolb‐Bachofen.  Uptake of toxic silica particles by isolated rat liver macrophages (Kupffer cells) is receptor mediated and can be blocked by competition. , 1992, The Journal of clinical investigation.

[35]  V. Lehto,et al.  Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Laetitia Gonzalez,et al.  Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells. , 2009, Small.

[37]  Nicolas H Voelcker,et al.  The biocompatibility of porous silicon in tissues of the eye. , 2009, Biomaterials.

[38]  R. Langer,et al.  Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Mauro Ferrari,et al.  Antibiological barrier nanovector technology for cancer applications , 2007, Expert opinion on drug delivery.

[40]  W. Kenneth Ward,et al.  A Review of the Foreign-body Response to Subcutaneously-implanted Devices: The Role of Macrophages and Cytokines in Biofouling and Fibrosis , 2008 .

[41]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[42]  M. Ghadiri,et al.  A porous silicon-based optical interferometric biosensor. , 1997, Science.

[43]  B. Basu.  Critical heat transfer analysis of pulsed laser melting of pure metals , 1991 .

[44]  Bengt Fadeel,et al.  Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. , 2009, Toxicology and applied pharmacology.

[45]  Samir Mitragotri,et al.  Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Michael J. Sailor,et al.  Polymer Replicas of Photonic Porous Silicon for Sensing and Drug Delivery Applications , 2003, Science.

[47]  E. Ruoslahti,et al.  Vascular zip codes in angiogenesis and metastasis. , 2004, Biochemical Society transactions.

[48]  J. B. Hall,et al.  Characterization of nanoparticles for therapeutics. , 2007, Nanomedicine.

[49]  E M Carlisle,et al.  Silicon: A Possible Factor in Bone Calcification , 1970, Science.

[50]  K A Moxon,et al.  Bioactive properties of nanostructured porous silicon for enhancing electrode to neuron interfaces , 2007, Journal of biomaterials science. Polymer edition.

[51]  D. Kiel,et al.  Dietary silicon intake and absorption. , 2002, The American journal of clinical nutrition.

[52]  M. Ferrari,et al.  Quantitative mechanics of endothelial phagocytosis of silicon microparticles , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[53]  L L Hench,et al.  Toxicology and biocompatibility of bioglasses. , 1981, Journal of biomedical materials research.

[54]  Priyabrata Mukherjee,et al.  High-porosity poly(epsilon-caprolactone)/mesoporous silicon scaffolds: calcium phosphate deposition and biological response to bone precursor cells. , 2008, Tissue engineering. Part A.